Goheal: In the era of high premiums, who is "paying" for the mergers and acquisitions of listed companies?

"The wonders of the world are often in dangerous and remote places." The journey of mergers and acquisitions of listed companies may seem magnificent at first glance, but in fact it is dangerous and far away. Behind every asset transfer, equity replacement, and valuation reshaping, it is like a mirage castle built on the capital wasteland - glamorous and grand, but it may collapse in the slightest disturbance. And the problem lies here: who will pay for this seemingly "high-end" capital game in the end?

If we compare mergers and acquisitions to a giant banquet, listed companies are the hosts, target companies are the main dishes, intermediaries are the exquisite platter chefs, and strategic investors are like "guest representatives" holding champagne, then who is the real payer?

Goheal has repeatedly seen a reality in his long-term merger and acquisition practice - small and medium shareholders are the "silent payers" after this feast.

American Goheal M&A Group

Those capital operations under the guise of "strategic upgrades" often ignite market sentiment in the short term, fueled by irrational expectations, and stock prices soar. However, in the cycle of "hot speculation-cash-out-thunder", retail investors are often at the end, and what they take on is the hot potato of stock price halving and goodwill impairment.

Taking the latest hot case as an example, a listed company mainly engaged in building materials announced a cross-border merger and acquisition of VR companies, which aroused widespread market attention. The concept theme was superimposed on the AI outlet, and the stock price once soared by 40%. But half a year later, as the "strategic investors" of the private placement, they had already cashed out and left the market, but small and medium-sized investors were trapped in a high-level pit. Goheal judged its transaction structure and found that this was a typical "closed loop of interest transfer" operation-locking price private placement, expected increase, lifting of restrictions on share reduction, and profit transfer.

More concealed is the "tacit collusion" between listed companies and target companies. Interestingly, such transactions often have three "magic attributes":

1. The valuation of the target is 3-4 times higher than the industry average;

2. The major shareholder is just approaching the warning line of the pledge rate;

3. The intermediary agency "rationally" endorses and charges a high commission of 2%+.

It sounds like God's will, but it is actually calculated by people.

For example, a consumer electronics company claimed to "strategically transform into life sciences" and acquired a genetic testing company. Its book net assets were only 80 million, but it was assessed as 1.5 billion, of which 1.32 billion was included in goodwill. The year after the transaction was completed, the company's performance did not meet expectations, and a goodwill impairment of 1 billion "destroyed" the shareholders' equity - this is the capital market's "high price entry, loss of money".

Goheal pointed out that behind such "false prosperity" is a set of seemingly legal institutional paths: off-balance sheet asset valuation, performance betting "customized contracts", compensation arrangements "going through the motions", and an important key - the deferred processing mechanism of goodwill impairment.

According to the current accounting system, goodwill does not need to be amortized year by year, but is mainly based on impairment testing, which creates a "delayed bomb" for high-premium mergers and acquisitions: the first two years seem calm, but as soon as the performance commitment period in the third year arrives, the "thunder" will sound. Data shows that from 2016 to 2025, 87% of high-premium mergers and acquisitions projects had goodwill impairment concentrated in the third year.

This is not a coincidence, but a concentrated realization of structural risks.

What is even more regrettable is the invisible allocation of institutional costs. When the target party fails to exit, the major shareholder successfully cashes out, and the intermediary collects service fees, how to deal with the remaining losses? Ordinary investors can only "silently bear" it.

The compensation mechanism is also unreliable. Although the regulatory requirements for the performance commitment party to pay in capital not less than 1% of the transaction amount, this 1% is often hidden in the SPV (special purpose vehicle), and some registered capital is only 100,000 yuan, and the performance ability is worrying. Goheal once assisted in the audit of a case and found that even if the project did not achieve the performance in the end, the compensation promise party successfully "legally avoided compensation" through shareholder circular guarantees and other means, and the actual compensation rate was less than 40%.

In addition to the institutional gaps, the market mechanism itself is also quietly distorted.

When traditional enterprises began to use the valuation logic of "Internet companies" to acquire industrial assets in order to hype the concept, the valuation anchor point of the entire secondary market began to drift. A paper listed company once valued a data marketing company based on PS (price-to-sales ratio), but ultimately suffered losses after the acquisition because the profits could not match.

What's more troublesome is that "cross-border" does not necessarily mean "synergy". The cash flow of the main business is forced to continue to "transfuse" new businesses, but the technology cannot be transferred, the channels are difficult to reuse, and the mismatch of resources exacerbates the business risks of the enterprise. Data shows that 73% of cross-border M&A projects have not truly achieved business integration, but have fallen into an infinite cycle of "financing-mergers-impairment".

In these capital illusions, supervision is not actually doing nothing. Since 2024, the China Securities Regulatory Commission has vigorously promoted new rules for the review of mergers and acquisitions, emphasizing key indicators such as paid-in capital, gambling arrangements, and reasonable valuation. Goheal observed that the proportion of reasonable valuation cases has increased from 23% in the past to 41%. But problems have also emerged - high-risk transactions with excessive cash payment ratios still account for more than 37%, indicating that there is still a lot of room for system optimization.

Some reform suggestions have surfaced: for example, the establishment of a follow-up investment mechanism for mergers and acquisitions funds requires that the lock-up period for all parties to mergers and acquisitions transactions shall not be less than 36 months; another example is the implementation of a combination of "cash + gambling" payment methods to prevent a one-shot deal and then get out of the whole body; another example is the construction of a dynamic goodwill monitoring system, which automatically triggers the review procedure once the goodwill/net asset ratio exceeds 50%.

These measures seem harsh, but they are the last line of defense to protect small shareholders.

After all, in the era of high premiums, every bubble in the market may eventually turn into a substantial loss for a small and medium-sized shareholder. Mergers and acquisitions should not be a stage for storytelling, but a field for realizing value.

Goheal is increasingly inclined to a criterion in the due diligence process of M&A projects: not to see how complex the transaction structure is or how exquisite the packaging is, but to see whether the cash flow in the next three years can support the acquisition price. This is the simplest logic and the most reliable truth.

Goheal Group

If you are a small and medium-sized investor, please remember: high-premium mergers and acquisitions are never opportunities for ordinary people, but often the stage for the strong to "arbitrage exit". Identifying the stage setting, recognizing the direction of the plot, and not being led by the "script" in the hands of the head players is the survival philosophy of the capital market.

Having written here, we would like to raise a question:

In the face of "flying valuation" M&A plans, which information do you pay more attention to? What M&A pits have you stepped on? What kind of mechanism do you think can truly protect small shareholders?

Welcome to leave a message for discussion. Goheal is willing to work with you to continue to speak out for the rational ecology of the capital market.

[About Goheal] Goheal is a leading investment holding company focusing on global mergers and acquisitions. It has deep roots in the three core business areas of acquisition of controlling rights of listed companies, mergers and acquisitions of listed companies, and capital operations of listed companies. With its profound professional strength and rich experience, it provides companies with full life cycle services from mergers and acquisitions to restructuring and capital operations, aiming to maximize corporate value and achieve long-term benefit growth.

特别声明:[Goheal: In the era of high premiums, who is "paying" for the mergers and acquisitions of listed companies?] 该文观点仅代表作者本人,今日霍州系信息发布平台,霍州网仅提供信息存储空间服务。

猜你喜欢

颗粒装车传送机 煤矿移动式扒渣机 皮带自动取料输送机(颗粒输送机械小型)

皮带输送机打滑的常见原因主要有四类:一是输送带张紧度不足,与滚筒之间的摩擦力不够,无法传递足够的动力;二是驱动滚筒表面粘料、胶层磨损,摩擦力下降,导致输送带打滑;三是输送量过载,超出设备额定承载能力,电机动…

颗粒装车传送机 煤矿移动式扒渣机 皮带自动取料输送机(颗粒输送机械小型)

陈汉典晒小S的红包🧧,这个红包🧧是满满满的祝福,很有你的风格(陈汉典小品)

2026年1月28日,陈汉典晒出了小S(徐熙娣)送给他的婚礼红包🧧和亲笔祝福卡。 小S手写的婚姻建议,简直可以称得上是综艺感十足的婚姻教科书。陈汉典则始终称小S为贵人,并表示他们在节目中的互动之所以如此有趣…

陈汉典晒小S的红包🧧,这个红包🧧是满满满的祝福,很有你的风格(陈汉典小品)

马年送礼佳品 可自选内容的定制马年礼盒任你搭配(马年送什么礼物🎁)

在此趋势中,广东书香香愈学院凭借对香文化与节庆礼仪的深入研究,推出多款以“马”为灵感、融合东方香道美学的定制礼盒,回应市场对高品质、有温度节庆礼品的需求。广东书香香愈学院在开发马年『香氛』礼盒时,并未简单套用生肖…

马年送礼佳品 可自选内容的定制马年礼盒任你搭配(马年送什么礼物🎁)

2026秋季最适合爷爷们的唐装男夹克,哪些款式值得入手?

2026秋季,给爷爷挑选一款合适的唐装男夹克成了一大难题。本文将从面料、设计、性价比等多方面为您全面解析,帮您选出最优质的春秋中老年唐装男夹克,让长辈们穿着舒适自在。无论是在日常生活中漫步街头,还是参加重要场合,这些精选的中山装新款都能展现

2026秋季最适合爷爷们的唐装男夹克,哪些款式值得入手?

君圣泰医药举办投资者交流会,分享CKM临床进展与研发战略(君圣实业集团有限公司)

在交流会的开篇,君圣泰医药创始人、董事长及首席执行官刘利平博士发表了“以长期价值,行稳致远”的致辞,刘博士简要回顾了公司在2025年里取得的丰硕成果,并展望了公司在2026年的发展规划,明确将继续深耕CKM…

君圣泰医药举办投资者交流会,分享CKM临床进展与研发战略(君圣实业集团有限公司)